Subtypes of α1-adrenoceptors in BPH: Future prospects for personalized medicine

Nature Clinical Practice Urology

Volumn 6, Issue 1, 2009, Pages 44-53

  Kojima, Yoshiyuki ^a   Sasaki, Shoichi ^a   Hayashi, Yutaro ^a   Tsujimoto, Gozoh ^b   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; NAFTOPIDIL; PHENYLEPHRINE; QUINAZOLINE; SILODOSIN; TAMSULOSIN; TERAZOSIN;

CELL GROWTH; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; GENE FUNCTION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; KNOCKOUT MOUSE; LOWER URINARY TRACT SYMPTOM; MICROARRAY ANALYSIS; MOLECULAR CLONING; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CLASSIFICATION; DECISION TREE; DRUG ANTAGONISM; FORECASTING; MALE; PHYSIOLOGY;

ANIMALS; DECISION TREES; FORECASTING; HUMANS; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 58549102740     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1276     Document Type: Review

References (85)

1. 1 -Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171: 1029-1035
2. 1-adrenoceptor pharmacology. Pharmacol Ther 98: 235-244
3. 1 -adrenoceptors: Consensus update. Pharmacol Rev 47: 267-70
4. 1 adrenergic receptor subtypes in human prostate. J Urol 150: 546-551
5. 1-adrenergic receptor subtypes in human tissues: Implications for human α-adrenergic physiology. Mol Pharmacol 45: 171-175
6. 1-adrenergic receptors by vessel bed and age. Circulation 100: 2336-2343
7. 1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 4: 366-378
8. Andersson KE (2007) LUTS treatment: Future treatment options. Neurourol Urodyn 26 (Suppl 6): S934-S947
9. 1 adrenoceptor function in health and disease from transgenic animal studies. Trends Endocrinol Metab 14: 107-113
10. 1-adrenoceptor subtypes present in the human prostate. Life Sci 54: 1595-1605
11. 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119: 797-803
12. Overbergh L et al. (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14: 33-43
13. Juhasz A et al. (2003) Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCP products. J Clin Lab Anal 17: 184-194
14. 1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 66 761-767
15. 1a-adrenoceptor in the human prostate. J Urol 154: 2096-2099
16. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 16: 21-28
17. 2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 47 (Suppl 2): S88-S119
18. 1d-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 161: 635-640
19. Lepor H et al. (1993) The α-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22: 301-307
20. 1c subtype. Mol Pharmacol 45 703-708
21. Andersson KE (2002) α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists. World J Urol 19: 390-396
22. Ikegaki I et al. (2000) Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia [Japanese]. Nippon Yakurigaku Zasshi 116: 63-69
23. 1 -adrenoceptors. Jpn J Pharmacol 79: 447-454
24. Gotoh M et al. (2005) Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial. BJU Int 96: 581-586
25. 1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int 97: 747-751
26. 1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 85 (Suppl 2): S6-S11
27. 1-Adrenergic receptor subtypes in human detrusor. J Urol 160 937-943
28. 1-adrenoceptor subtypes in the human prostate: Functional and binding studies. Br J Urol 74: 572-578
29. 1a adrenoceptors in human prostate by tissue segment binding. J Urol 177: 377-381
30. Hayase M et al. (2008) Mechanisms of human prostate smooth muscle spontaneous contraction. J Urol 179 (Suppl 4): S454-S455
31. Exintaris B et al. (2002) Spontaneous slow wave and contractile activity of the guinea pig prostate. J Urol 168: 315-322
32. 1 -Adrenoceptor subtypes. Eur J Pharmacol 375: 261-276
33. 1b-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91: 10109-10113
34. Kyprianou N (2003) Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J Urol 169: 1520-1525
35. 1-adrenoceptor subtype in prostatic growth in a benign prostatic hyperplasia model rat [abstract #1316]. J Urol 179 (Suppl 4): S451
36. 1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 12: 444-451
37. Garrison JB and Kyprianou N (2006) Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 66: 464-472
38. McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398
39. Kip1. J Biol Chem 278 672-678
40. 1-adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells. Biochem Biophys Res Commun 272: 906-911
41. Oda N et al. (2003) New experimental model for benign prostate hyperplasia, stromal hyperplasia in rodents [abstract]. J Urol 169 (Suppl 4): S279
42. Caine M et al. (1978) A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50: 551-554
43. Lepor H et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474
44. Gillenwater JY et al. (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essentiat hypertension: A double-blind, placebo-controlled, dose-response multicenter study. J Urol 154: 110-115
45. 1 -Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 3: 76-63
46. 1b-adrenergic receptor. Proc Natl Acad Sci USA 94: 11589-11594
47. 1b-adrenergic receptor defect in mice. Circulation 105: 1700-1707
48. 1-adrenoceptors. Eur Urol 36 (Suppl 1): S2-S6
49. 1a -adrenoceptor antagonist: A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29: 155-167
50. 1-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98: 1019-1024
51. 1-Adrenoceptors and ejacaculatory function. Br J Pharmacol 152: 289-290
52. 1 adrenoceptors: Binding, functional and in vivo studies. Br J Pharmacol 118: 871-878
53. Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 58 953-959
54. McKeage K and Plosker GL (2002) Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 62: 633-653
55. 1 adrenergic receptor knockout mice. Biochem Pharmacol 73 1107-1112
56. 1d-adrenoceptor. J Urol 174: 370-374
57. 1 -Adrenoceptors are required for normal male sexual function. Br J Pharmacol 152: 332-340
58. 1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155: 103-109
59. Vivekandan P and Singh OV (2008) High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics 5: 45-60
60. Romero R et al. (2008) The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG 113 (Suppl 3): S118-S135
61. Ikemoto I et al. (2003) Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two-drug crossover study. Int J Urol 10: 587-594
62. Marsh S (2007) Pharmacogenomics. Ann Oncol 18 (Suppl 9): S24-S28
63. Singh A (2007) Pharmacogenomics - the potential of genetically guided prescribing. Aust Fam Physician 36: 820-824
64. Giacomini KM et al. (2007) The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81: 326-345
65. Mushiroda T et al. (2006) Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51: 249-253
66. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97 10483-10488
67. Koo SH and Lee EJ (2006) Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol 33: 525-532
68. Flordellis C et al. (2004) Pharmacogenomics of adrenoceptors. Pharmacogenomics 5: 803-817
69. 1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci 25: 449-455
70. 1c adrenergic receptor gene (ADRA1C). Hum Mol Genet 1: 349
71. 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 118: 1403-140
72. 1a-adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther 75: 539-545
73. 1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. BJU Int 97: 852-855
74. 1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch Pharmacol 371: 229-239
75. Sadée W and Dai Z (2005) Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14: R207-R214
76. Fan JB et al. (2006) Highly parallel genomic assays. Nat Rev Genet 7: 632-644
77. Hao K et al. (2008) Calibrating the performance of SNP arrays for whole-genome association studies. PLoS Genet 4: E1000109
78. 1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J Urol 179: 1040-1046
79. Chen JJ (2007) Key aspects of analyzing microarray gene-expression data. Pharmacogenomics 8: 473-482
80. Prakash K et al. (2002) Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proc Natl Acad Sci USA 99: 7598-7603
81. Luo J et al. (2002) Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51 189-200
82. 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest 90: 1763-1768
83. 1-adxrenoceptors in the rat prostate. J Urol 172: 2465-2470
84. 1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate 67: 1285-1292
85. Yono M et al. (2005) Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling. Life Sci 77: 470-479